Earendil: A Blueprint for a Multipolar Life Sciences Era
By Joe Renny
June 5, 2026
The $787M financing points to a new global architecture in biotech
5 min read
False
Advertisement
Outsourcing
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
What Sponsors Get Wrong When Initiating an Oncology Study
By Luke Gill, Claudio Hegenberger
May 4, 2026
How CRO selection significantly influences study outcomes
6 min read
Building Quality into Advanced Therapies from Day One
March 13, 2026
Why early, risk-based thinking is critical in cell and gene therapy development
5 min read
Quality Without Complexity: Interviewing Dipesh Patel
February 4, 2026
“Giving people enough space and a safe environment to do their job and innovate is fulfilling for them, and they will then, inevitably, develop solutions to the most pressing needs.”
4 min read
How AI and CDMO/CRO Integration is Key to the Future of Drug Development
By Jennifer Cannon
February 3, 2026
The next era of drug development will be connected, data-driven and centered on patient impact
4 min read
ten23 health and BD Partner to Address Demand for Self-Administered Therapies
January 30, 2026
Partnership enables supply chain readiness of BD Libertas™ wearable injector as full-service solution
1 min read
The Strategic Questions Reshaping the CDMO Map
January 22, 2026
We sit down with Joerg Ahlgrimm, CEO of SK pharmteco, to discuss his career and the changing landscape for outsourcing
9 min read
How Speed, Scale, and Science Can Personalize the Pandemic Response
By Andrew Lewis
January 20, 2026
Decades of research have made mRNA a platform for fast, flexible therapeutic innovation, but its promise depends on partnerships.
4 min read
Why Europe’s CDMO Sector Must Learn to Dance with Disruption
By Joe Renny
January 14, 2026
For CDMOs, the storms of de-industrialization, Brexit, and the Biosecure Act are not existential threats but the very winds that can propel them forward.
4 min read
